|Bid||23.50 x 1400|
|Ask||24.38 x 800|
|Day's Range||21.97 - 24.00|
|52 Week Range||17.11 - 24.75|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||26.50|
Castle Biosciences, Inc. today announced that it will release its financial results for the second quarter ended June 30, 2019 after the close of market on Tuesday, September 3, 2019.
Castle Biosciences, Inc. , announced today the closing of its previously announced initial public offering of 4,600,000 shares of its common stock, which includes 600,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $16.00 per share.
The shares are expected to begin trading on The Nasdaq Global Market on July 25, 2019 under the symbol "CSTL." All of the common stock in the offering is being offered by Castle Biosciences. In addition, Castle Biosciences has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock. Copies of the final prospectus related to the offering, when available, may be obtained from: SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone: (800) 808‐7525, ext.
Friendswood, Texas-based Castle Biosciences, Inc. proposes to offer 3.33 million shares in an IPO, according to a S-1/A filing. The shares of the company have been approved for listing on the Nasdaq under the ticker symbol CSTL. SVB Leerink and Baird are the joint book-running managers for the offering, while Canaccord Genuity and BTIG are co-managers.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Castle Biosciences Inc (NASDAQ: CSTL ) will issue more than 3.33 million ...